Please provide your email address to receive an email when new articles are posted on . Generic oral alendronate or generic parenteral zoledronate were the most cost-effective therapies in the United ...

Please provide your email address to receive an email when new articles are posted on . Compared with other first-line osteoporosis treatments, alendronate therapy yielded an increased risk for ...

Miami, FL - The adverse event of jaw osteonecrosis--reported with the use of intravenous bisphosphonates in cancer patients--has also been seen with the use of oral bisphosphonates in osteoporosis ...

Alendronate significantly reduces the risk of cardiovascular events in patients treated with the bisphosphonate following a hip fracture, the first population-based study of its kind indicates. "One ...

Giving zoledronate every 18 months for 6 years reduced the risk of fragility fractures—both vertebral and nonvertebral—in older women with hip bone mineral density indicating osteopenia, a ...

To counter the decline in BMD after denosumab treatment is discontinued, osteoporosis patients may be transitioned from denosumab to other anti-resorptives. This report investigates whether a single ...

Research has found that a drug normally given to osteoporosis sufferers could provide effective pain relief to patients with knee and hip osteoarthritis. St George's, University of London research has ...

Denosumab is a monoclonal antibody which acts as a potent anti-resorptive agent and is now widely used in the treatment of osteoporosis. However, when treatment is discontinued, bone resorption ...